Tesla's autopilot beats humans + big pharma moves

🌅 Today's Morning Call

S&P Futures 7,542.00 ▼ -13.00 (-0.17%)	Nasdaq Futures 30,419.25 ▲ +20.50 (+0.07%)	Dow Futures 52,034.00 ▼ -208.00 (-0.40%)
10Y Treasury 4.46% ▲ +0.04%	US Dollar 100.79 ▲ +0.56 (+0.55%)	Bitcoin $63,894 ▼ -$559 (-0.87%)

Good morning! Thursday is serving up a split screen: Nasdaq futures are nudging higher while the Dow is dragging its feet, down over 200 points in pre-market trading. Yields are creeping up again, the dollar is flexing, and there is no shortage of headlines to work through before the opening bell. From a massive cybersecurity acquisition to a clinical trial miss that is going to sting, here is what you need to know before the market opens.

👀 What to Watch Today

Thursday's session has plenty of scheduled catalysts to track. On the economic front, keep an eye on weekly jobless claims data hitting the tape this morning, which will feed directly into rate sentiment given the 10-year yield is already nudging up to 4.46%. Any surprise in either direction could shift the tone quickly.

Earnings-wise, Kroger (KR) already reported before the bell and beat first-quarter sales estimates, so watch how the stock opens and whether grocery sector peers get a lift. The FDA advisory panel vote on Moderna's (MRNA) mRNA flu vaccine for older adults is also a major event today. That committee decision could move the stock meaningfully in either direction and has broader implications for the mRNA platform story.

On the deal front, Accenture's (ACN) $4.18 billion cybersecurity acquisition announcement will have analysts re-rating the stock's growth thesis all morning. Watch how the broader cybersecurity sector reacts, as large strategic acquisitions often lift the whole neighborhood.

Big Oil Threatened by New Fuel Unlocking FREE, Endless Power [ad]

🌏 Overnight Recap

Overnight, global markets were largely cautious. European indices traded mixed as investors digested central bank commentary and kept a watchful eye on dollar strength. The DXY climbing to 100.79 is putting quiet pressure on emerging market currencies and commodity prices, and that tone carried through the Asian session as well.

On the energy front, Saudi Aramco (via ETFs IEO, IYE, and KSA) made news with reports that it is considering expanding its global oil storage capacity in the wake of the Iran conflict. The move signals that geopolitical risk in the Middle East is still very much shaping long-term energy infrastructure strategy.

Bitcoin slipped below $64,000 overnight, sitting at $63,894, which is adding a mild risk-off undercurrent to sentiment this morning. The crypto pullback, combined with rising short-end yields on the 5-year Treasury now at 4.23%, suggests traders are not exactly racing into speculative positions heading into today's open.

Why Elon actually needs the SpaceX IPO [ad]

📊 Pre-Market Movers

Novocure (NVCR) is the name everyone is going to be talking about this morning, and not in a good way. The company's Tumor Treating Fields therapy failed to hit the primary endpoint in a late-stage trial for newly diagnosed brain tumors. Clinical trial misses of this magnitude tend to be brutal for biotech stocks, and NVCR is likely to open sharply lower.

On the brighter side, Tesla (TSLA) is getting some quiet love from a BofA analyst who reviewed Waymo and Tesla safety data and found serious incidents are genuinely rare. This is not a blowout catalyst, but it reinforces the autonomous driving narrative that has been central to TSLA's valuation thesis. Shares are responding positively in pre-market.

Merck (MRK) also scored a win overnight with the FDA approving expanded use of its pneumococcal vaccine for high-risk children and teens. It is not a market-moving headline on its own, but it adds a positive regulatory data point to Merck's pipeline story heading into the session. BHP is the other one to watch after flagging a $2.3 billion charge on its Jansen potash project cost overruns.

He Called NVIDIA at $1.10 – Now He Says, “SELL” [ad]

🔍 Today's Watchlist

1. TSLA: BofA safety data review is a quiet but meaningful bullish catalyst. Watch for analyst follow-through.
2. MRNA: FDA advisory panel votes today on the mRNA flu vaccine. Binary event with big price-move potential.
3. NVCR: Brain tumor trial missed its primary endpoint. Expect heavy selling pressure at the open.
4. ACN: $4.18B cybersecurity deal announced. Watch how the market prices the growth versus cost tradeoff.
5. 10-Year Yield at 4.46%: Rising rates are squeezing rate-sensitive sectors. Keep utilities and REITs on your radar.

🎯 The Morning Playbook

Today's session is a stock picker's market more than a macro momentum day. Futures are mixed, there is no single dominant theme pulling everything in one direction, and the real action is going to be company-specific. That actually creates opportunity if you know where to look.

The MRNA FDA vote is the single highest-conviction event of the day. If the advisory panel gives a thumbs up on the mRNA flu vaccine for older adults, the stock could see a sharp move higher and reignite enthusiasm for the platform broadly. If it goes the other way, expect pressure not just on MRNA but on the mRNA space as a concept.

The broader takeaway this morning is simple: rising yields, a stronger dollar, and mixed futures mean the easy money trade is not obvious today. Focus on the names with real catalysts, manage your risk around binary events like MRNA, and let the noise settle before chasing anything. Patience is a strategy too.

How to collect $1,170/month from silver [ad]